195 related articles for article (PubMed ID: 33594386)
1. Apomorphine hydrochloride: a sublingual tablet for the OFF episodes in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2021 Jan; 57(1):5-16. PubMed ID: 33594386
[TBL] [Abstract][Full Text] [Related]
2. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
3. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
5. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
6. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Caughman CY; Factor S
Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
[No Abstract] [Full Text] [Related]
7. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
[No Abstract] [Full Text] [Related]
8. On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Olanow CW; Poewe W; Rascol O; Stocchi F
Mov Disord; 2021 Oct; 36(10):2244-2253. PubMed ID: 34363424
[TBL] [Abstract][Full Text] [Related]
9. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
10. [Apomorphine in the treatment of Parkinson's Disease].
Dressler D
Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
[TBL] [Abstract][Full Text] [Related]
11. Sublingual apomorphine in treatment of Parkinson's disease: a review.
Hislop J; Margolesky J; Shpiner DS
Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
[TBL] [Abstract][Full Text] [Related]
12. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
[No Abstract] [Full Text] [Related]
13. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
14. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.
Courty E; Durif F; Zenut M; Courty P; Lavarenne J
Clin Neuropharmacol; 1997 Apr; 20(2):140-7. PubMed ID: 9099466
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
17. Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.
Martinez-Nunez AE; LeWitt PA
J Parkinsons Dis; 2023; 13(4):441-451. PubMed ID: 37182902
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
20. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]